Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of Sun Yat-sen University(Medical Sciences) ; (6): 731-738, 2019.
Artigo em Chinês | WPRIM | ID: wpr-817744

RESUMO

@# 【Objective】To summarize current situation of multiple sclerosis in South China and provide reference for MS diagnosis and treatment.【Methods】We selected patients of whom the first diagnosis was MS from 2011 to March 2019,and divided them into Adults group and Pediatrics group according to onset age above or below 14. We analyzed them from epidemiology,symptomatology,accessory examinations and treatment situation.【Results】296 patients were admitted into this research. The ratio of male to female was 1∶1.67. Median onset age was 26. Relapsing-remitting MS accounted for 63.2% of all patients. For initial episode,130 patients had motor symptoms(43.9%),118 patients showed sensory symptoms(39.9%),and 55 patients were accompanied with visual symptoms(18.6%). Statistical difference exists in sensory symptoms(114 vs. 4,Z = -2.155,P = 0.031)and paroxysmal symptoms(4 vs. 3,Z = -3.610,P = 0.000) of Adults group and Pediatrics group. For following episodes,the total relapsing time was 712,with motor symptoms relapsing 380 times(53.4%),sensory symptoms 265 times(37.2%)and visual symptoms 134 times(18.8%). Statistical difference existed in motor,sensory,visual,other ocular symptoms and paroxysmal symptoms. Positive rate of Oligoclonal bond was 45.5%. Positive rate of MOG-Ab was 16.7%. For brain MRI,periventricular lesions ≥ 9 accounted for 57.4% of all patients,with cortical & juxtacortical lesions 28.1% and infratentorial lesions 0.3%. Patients who had optic nerve lesions accounted for 63.2%. No statistical difference existed in them. For treatment,drugs they had used previously were glucocorticoid(79.7%),beta Interferon(15.9%)and azathioprine(13.9%).During the study,drugs they were using were glucocorticoid(15.5%),rituximab(9.1%),azathioprine(8.1%)and teriflunomide(8.1%).【Conclusions】For gender, age,symptomatology and accessory examinations,results of this research are similar to previous papers about multiple sclerosis in Asian. For treatment,the trend indicates that usage of new disease-modifying drugs goes up.

2.
Chinese Medical Journal ; (24): 3439-3445, 2013.
Artigo em Inglês | WPRIM | ID: wpr-354457

RESUMO

<p><b>BACKGROUND</b>Our previous study had demonstrated that ulinastatin (UTI) had a neuroprotective effect in experimental autoimmune encephalomyelitis (EAE). Methylprednisolone has been recommended to be a standard drug in multiple sclerosis (MS) therapies. The present study was to investigate the protective effects of UTI combined methylprednisolone in EAE.</p><p><b>METHODS</b>Mice were divided into a UTI treatment group, a methylprednisolone treatment group, a combined treatment group with UTI and methylprednisolone, a normal saline treatment group, and a normal control group. EAE mice were induced in groups receiving different combined treatments, or respective monotherapies. Demyelination was evaluated by Solochrome cyanin staining. 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP)/ myelin basic protein (MBP)/ the precursor form of nerve growth factor (proNGF)/p75/ inducible nitric oxide synthase (iNOS) proteins in cerebral cortex of EAE were detected by Western blotting.</p><p><b>RESULTS</b>The combined treatment group had a lower clinical score (0.61 ± 0.06) and demyelinating score (1.33 ± 0.33) than the groups with normal saline (clinical score: 1.39 ± 0.08, P < 0.001; demyelinating score: 2.75 ± 0.49, P < 0.05) or monotheraphies. Compared with the saline treated EAE group, UTI combined methylprednisolone significantly increased expressions of CNP (1.14 ± 0.06 vs. 0.65 ± 0.04, P < 0.001), MBP (1.28 ± 0.14 vs. 0.44 ± 0.17, P < 0.001), and decreased expressions of proNGF (1.08 ± 0.10 vs. 2.32 ± 0.12, P < 0.001), p75 (1.13 ± 0.13 vs. 2.33 ± 0.17, P < 0.001), and iNOS (1.05 ± 0.31 vs. 2.17 ± 0.13, P < 0.001) proteins in EAE. Furthermore, UTI combined methylprednisolone could significantly upregulate MBP (1.28 ± 0.14 vs. 1.01 ± 0.15, P < 0.05) expression and downregulate iNOS (1.05 ± 0.31 vs. 1.35 ± 0.14, P < 0.05) expression compared to methylprednisolone treatment EAE group. And proNGF expression was significantly lower in combined treatment (1.08 ± 0.10) than that in UTI (1.51 ± 0.24, P < 0.05) or methylprednisolone (1.31 ± 0.04, P < 0.05) treatment group.</p><p><b>CONCLUSION</b>Combination treatment of UTI with methylprednisolone was shown to protect EAE, suggesting that combination therapy is a potential novel treatment in MS.</p>


Assuntos
Animais , Feminino , Camundongos , Combinação de Medicamentos , Encefalomielite Autoimune Experimental , Tratamento Farmacológico , Glicoproteínas , Usos Terapêuticos , Metilprednisolona , Usos Terapêuticos , Camundongos Endogâmicos C57BL , Esclerose Múltipla , Tratamento Farmacológico
3.
Chinese Journal of Biotechnology ; (12): 30-34, 2003.
Artigo em Chinês | WPRIM | ID: wpr-270043

RESUMO

By the method of single preimplantation embryos differential display polymerase chain reaction (SPEDDRT-PCR), 25 reprogramming cDNA fragments were obtained from single 2-cell, 8-cell embryos and blastula. After cloning and sequencing, five of them were identified by reverse-Northern and characterized with stage-specific expression during reconstructed embryo development. This results will help to isolate full length reprogramming genes and study their function during embryonic development.


Assuntos
Animais , Feminino , Gravidez , Coelhos , Blastocisto , Metabolismo , Fisiologia , Northern Blotting , Embrião de Mamíferos , Metabolismo , Desenvolvimento Embrionário , Genética , Fisiologia , Regulação da Expressão Gênica no Desenvolvimento , Genética , Fisiologia , Reação em Cadeia da Polimerase
4.
Chinese Journal of Biotechnology ; (12): 79-83, 2002.
Artigo em Chinês | WPRIM | ID: wpr-231368

RESUMO

This study was carried out to examine the effect of different donor cell type and micro-manipulation on the development of reconstituted embryos. Cultured mural cumulus cells or fibroblast cells from an adult transgenic goat expressing human erythropoietin(rhEPO) were used as the donor cells in nuclear transfer experiments. The reconstituted eggs were generated by transferring fibroblast cells or cumulus cells into the perivitelline space of enucleated M II oocytes and then followed by electrofusion and activation. After 6 days' incubation in vivo, the reconstructed embryos developed into morulae or blastocysts were transferred into 6 foster recipients. Two of the foster-mothers were pregnant and gave birth to two offspring, which were derived from the fibroblast cell and cumulus cell, respectively. Fingerprint analysis showed that the PCR-RFLP patterns of the two offspring were identical to that of donor goats. PCR results indicated that these cloned goats carried hEPO gene as same as their donor cells.


Assuntos
Animais , Humanos , Animais Geneticamente Modificados , Genética , Fusão Celular , Métodos , Clonagem de Organismos , Transferência Embrionária , Eritropoetina , Genética , Fibroblastos , Biologia Celular , Cabras , Embriologia , Genética , Microinjeções , Métodos , Técnicas de Transferência Nuclear , Oócitos , Biologia Celular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA